Supplementary Table 3. Soluble programmed cell death ligand 1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis

Supplementary Table 3. Soluble programmed cell death ligand 1 as a predictive biomarker in lung cancer: a systematic review and meta-analysisSummary of additional characteristics of eligible studies<br>AbstractBackground: We performed a meta-analysis to evaluate the association between soluble programmed cell death ligand 1 (sPD-L1) and survival outcomes and treatment response in lung cancer. Methods &amp; methods: Eligible studies were obtained by searching PubMed, EMBASE and Web of Science. Pooled effect estimates were calculated for overall survival (OS), progression-free survival (PFS) and objective response rate (ORR). Results: Twelve eligible studies with 1188 lung cancer patients were included. High sPD-L1 was significantly associated with worse OS (hazard ratio [HR]=2.20, 95%CI: 1.59-3.05, P&lt;0.001) and PFS (HR=2.42, 95%CI: 1.72-3.42, P&lt;0.001) in patients treated with immune checkpoint inhibitors (ICIs). Meanwhile, high sPD-L1 predicted worse OS (HR=1.60, 95%CI: 1.31-1.96, P&lt;0.001) and lower ORR (odds ratio=0.52, 95%CI: 0.35-0.80, P=0.002) in patients treated with non-ICI therapies. Conclusion: sPD-L1 is a potential predictive biomarker of lung cancer. <br>